* prior exposure to sars-cov-2 * receipt of any vaccine from 4 weeks prior to each trial vaccination (8 weeks for live vaccines) to 6 weeks after each trial vaccination * previous rmva immunization * known allergy to the components of the sars-cov-2 vaccine product * known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine * evidence in the subject's medical history or in the medical examination that might influence either the safety of the subject or the absorption, distribution, metabolism or excretion of the investigational product * clinically relevant findings in ecg * any confirmed or suspected immunosuppressive or immunodeficient condition, cytotoxic therapy in the previous 5 years, and/or diabetes * any chronic or active neurologic disorder, including seizures, and epilepsy, excluding a single febrile seizure as a child exclusion criteria for the subjects before the 3rd/4th (=booster) vaccination: 1. prior infection with sars-cov-2 in medical history (documented by pcr test) 2. receipt of any vaccine from 2 weeks prior to each trial vaccination (4 weeks for live vac-cines) to 2 weeks after each trial vaccination. 3. receipt any covid-19 vaccine (investigational or licensed other than mva-sars-2-s be-fore vaccination throughout end of study). 4. known allergy to the components of t comirnaty®. 5. known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine. 6. participation in a clinical trial other than the mva-sars-2-s vaccine trial or use of an in-vestigational product other than mva-sars-2-s within 30 days or five times the half-life of the investigational product -whichever is longer- prior to receiving the first dose within this study. 7. evidence in the subject's medical history or in the medical examination that might influence

* prior exposure to sars-cov-2 * receipt of any vaccine from 4 weeks prior to each trial vaccination (8 weeks for live vaccines) to 6 weeks after each trial vaccination * previous rmva immunization * known allergy to the components of the sars-cov-2 vaccine product * known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine * evidence in the subject's medical history or in the medical examination that might influence either the safety of the subject or the absorption, distribution, metabolism or excretion of the investigational product * clinically relevant findings in ecg * any confirmed or suspected immunosuppressive or immunodeficient condition, cytotoxic therapy in the previous 5 years, and/or diabetes * any chronic or active neurologic disorder, including seizures, and epilepsy, excluding a single febrile seizure as a child exclusion criteria for the subjects before the 3rd/4th (=booster) vaccination: 1. prior infection with sars-cov-2 in medical history (documented by pcr test) 2. receipt of any vaccine from 2 weeks prior to each trial vaccination (4 weeks for live vac-cines) to 2 weeks after each trial vaccination. 3. receipt any covid-19 vaccine (investigational or licensed other than mva-sars-2-s be-fore vaccination throughout end of study). 4. known allergy to the components of t comirnaty®. 5. known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine. 6. participation in a clinical trial other than the mva-sars-2-s vaccine trial or use of an in-vestigational product other than mva-sars-2-s within 30 days or five times the half-life of the investigational product -whichever is longer- prior to receiving the first dose within this study. 7. evidence in the subject's medical history or in the medical examination that might influence

prior exposure to sars-cov-2 receipt of any vaccine from 4 weeks prior to each trial vaccination (8 weeks for live vaccines) to 6 weeks after each trial vaccination previous rmva immunization known allergy to the components of the sars-cov-2 vaccine product known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine evidence in the subject's medical history or in the medical examination that might influence either the safety of the subject or the absorption, distribution, metabolism or excretion of the investigational product clinically relevant findings in ecg any confirmed or suspected immunosuppressive or immunodeficient condition, cytotoxic therapy in the previous 5 years, and/or diabetes any chronic or active neurologic disorder, including seizures, and epilepsy, excluding a single febrile seizure as a child exclusion criteria for the subjects before the 3rd/4th (=booster) vaccination: prior infection with sars-cov-2 in medical history (documented by pcr test) receipt of any vaccine from 2 weeks prior to each trial vaccination (4 weeks for live vac-cines) to 2 weeks after each trial vaccination. receipt any covid-19 vaccine (investigational or licensed other than mva-sars-2-s be-fore vaccination throughout end of study). known allergy to the components of t comirnaty®. known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine. participation in a clinical trial other than the mva-sars-2-s vaccine trial or use of an in-vestigational product other than mva-sars-2-s within 30 days or five times the half-life of the investigational product -whichever is longer- prior to receiving the first dose within this study. evidence in the subject's medical history or in the medical examination that might influence

prior exposure to sars-cov-2 receipt of any vaccine from 4 weeks prior to each trial vaccination (8 weeks for live vaccines) to 6 weeks after each trial vaccination previous rmva immunization known allergy to the components of the sars-cov-2 vaccine product known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine evidence in the subject's medical history or in the medical examination that might influence either the safety of the subject or the absorption, distribution, metabolism or excretion of the investigational product clinically relevant findings in ecg any confirmed or suspected immunosuppressive or immunodeficient condition, cytotoxic therapy in the previous 5 years, and/or diabetes any chronic or active neurologic disorder, including seizures, and epilepsy, excluding a single febrile seizure as a child exclusion criteria for the subjects before the 3rd/4th (=booster) vaccination: prior infection with sars-cov-2 in medical history (documented by pcr test) receipt of any vaccine from 2 weeks prior to each trial vaccination (4 weeks for live vac-cines) to 2 weeks after each trial vaccination. receipt any covid-19 vaccine (investigational or licensed other than mva-sars-2-s be-fore vaccination throughout end of study). known allergy to the components of t comirnaty®. known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine. participation in a clinical trial other than the mva-sars-2-s vaccine trial or use of an in-vestigational product other than mva-sars-2-s within 30 days or five times the half-life of the investigational product -whichever is longer- prior to receiving the first dose within this study. evidence in the subject's medical history or in the medical examination that might influence

- prior exposure to sars-cov-2 - receipt of any vaccine from 4 weeks prior to each trial vaccination (8 weeks for live vaccines) to 6 weeks after each trial vaccination - previous rmva immunization - known allergy to the components of the sars-cov-2 vaccine product - known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine - evidence in the subject's medical history or in the medical examination that might influence either the safety of the subject or the absorption, distribution, metabolism or excretion of the investigational product - clinically relevant findings in ecg - any confirmed or suspected immunosuppressive or immunodeficient condition, cytotoxic therapy in the previous 5 years, and/or diabetes - any chronic or active neurologic disorder, including seizures, and epilepsy, excluding a single febrile seizure as a child exclusion criteria for the subjects before the 3rd/4th (=booster) vaccination: 1. prior infection with sars-cov-2 in medical history (documented by pcr test) 2. receipt of any vaccine from 2 weeks prior to each trial vaccination (4 weeks for live vac-cines) to 2 weeks after each trial vaccination. 3. receipt any covid-19 vaccine (investigational or licensed other than mva-sars-2-s be-fore vaccination throughout end of study). 4. known allergy to the components of t comirnaty®. 5. known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine. 6. participation in a clinical trial other than the mva-sars-2-s vaccine trial or use of an in-vestigational product other than mva-sars-2-s within 30 days or five times the half-life of the investigational product -whichever is longer- prior to receiving the first dose within this study. 7. evidence in the subject's medical history or in the medical examination that might influence

- prior exposure to sars-cov-2 - receipt of any vaccine from 4 weeks prior to each trial vaccination (8 weeks for live vaccines) to 6 weeks after each trial vaccination - previous rmva immunization - known allergy to the components of the sars-cov-2 vaccine product - known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine - evidence in the subject's medical history or in the medical examination that might influence either the safety of the subject or the absorption, distribution, metabolism or excretion of the investigational product - clinically relevant findings in ecg - any confirmed or suspected immunosuppressive or immunodeficient condition, cytotoxic therapy in the previous 5 years, and/or diabetes - any chronic or active neurologic disorder, including seizures, and epilepsy, excluding a single febrile seizure as a child exclusion criteria for the subjects before the 3rd/4th (=booster) vaccination: 1. prior infection with sars-cov-2 in medical history (documented by pcr test) 2. receipt of any vaccine from 2 weeks prior to each trial vaccination (4 weeks for live vac-cines) to 2 weeks after each trial vaccination. 3. receipt any covid-19 vaccine (investigational or licensed other than mva-sars-2-s be-fore vaccination throughout end of study). 4. known allergy to the components of t comirnaty®. 5. known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine. 6. participation in a clinical trial other than the mva-sars-2-s vaccine trial or use of an in-vestigational product other than mva-sars-2-s within 30 days or five times the half-life of the investigational product -whichever is longer- prior to receiving the first dose within this study. 7. evidence in the subject's medical history or in the medical examination that might influence

- prior exposure to sars-cov-2 - receipt of any vaccine from 4 weeks prior to each trial vaccination (8 weeks for live vaccines) to 6 weeks after each trial vaccination - previous rmva immunization - known allergy to the components of the sars-cov-2 vaccine product - known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine - evidence in the subject's medical history or in the medical examination that might influence either the safety of the subject or the absorption, distribution, metabolism or excretion of the investigational product - clinically relevant findings in ecg - any confirmed or suspected immunosuppressive or immunodeficient condition, cytotoxic therapy in the previous 5 years, and/or diabetes - any chronic or active neurologic disorder, including seizures, and epilepsy, excluding a single febrile seizure as a child

- prior exposure to sars-cov-2 - receipt of any vaccine from 4 weeks prior to each trial vaccination (8 weeks for live vaccines) to 6 weeks after each trial vaccination - previous rmva immunization - known allergy to the components of the sars-cov-2 vaccine product - known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine - evidence in the subject's medical history or in the medical examination that might influence either the safety of the subject or the absorption, distribution, metabolism or excretion of the investigational product - clinically relevant findings in ecg - any confirmed or suspected immunosuppressive or immunodeficient condition, cytotoxic therapy in the previous 5 years, and/or diabetes - any chronic or active neurologic disorder, including seizures, and epilepsy, excluding a single febrile seizure as a child